Randomized phase II study comparing S-1 plus Leucovorin (SL) versus S-1 alone in patients with gemcitabine-refractory advanced pancreatic cancer (APC)

被引：0
|
作者：
Okusaka, T. [1 ]
Ueno, M. [2 ]
Omuro, Y. [3 ]
Isayama, H. [4 ]
Fukutomi, A. [5 ]
Ikeda, M. [6 ]
Mizuno, N. [7 ]
Fukuzawa, K. [8 ]
Hyodo, I. [9 ]
Boku, N. [10 ]
机构：
[1] Natl Canc Ctr, Tokyo, Japan
[2] Kanagawa Canc Ctr, Div Hepatobiliary & Pancreat Med Oncol, Kanagawa, Japan
[3] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Chemotherapy, Tokyo, Japan
[4] Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Tokyo, Japan
[5] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Shizuoka, Japan
[6] Natl Canc Ctr Hosp East, Div Hepatobiliary & Pancreat Oncol, Chiba, Japan
[7] Aichi Canc Ctr Hosp, Dept Gastroenterol, Nagakute, Aichi, Japan
[8] Oita Red Cross Hosp, Dept Surg, Oita, Japan
[9] Univ Tsukuba, Div Gastroenterol, Tsukuba, Ibaraki, Japan
[10] St Marianna Univ, Sch Med, Dept Clin Oncol, Kawasaki, Kanagawa, Japan
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2578
引用
收藏
页码：S611 / S611
页数：1
相关论文
共 50 条
  • [21] Retrospective Study of Gemcitabine plus S-1 versus Gemcitabine Alone in Cases with Unresectable Advanced Pancreatic Cancer
    Suzuki, Shuji
    Ozaki, Yuhi
    Saida, Shin
    Kaji, Satoshi
    Koike, Nobusada
    Harada, Nobuhiko
    Hayashi, Tsuneo
    Suzuki, Mamoru
    HEPATO-GASTROENTEROLOGY, 2013, 60 (124) : 916 - 920
  • [22] A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer
    Suzuki, Eiichiro
    Ikeda, Masafumi
    Okusaka, Takuji
    Nakamori, Shoji
    Ohkawa, Shinichi
    Nagakawa, Tatsuya
    Boku, Narikazu
    Yanagimoto, Hiroaki
    Sato, Tosiya
    Furuse, Junji
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (05) : 1141 - 1146
  • [23] A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer
    Eiichiro Suzuki
    Masafumi Ikeda
    Takuji Okusaka
    Shoji Nakamori
    Shinichi Ohkawa
    Tatsuya Nagakawa
    Narikazu Boku
    Hiroaki Yanagimoto
    Tosiya Sato
    Junji Furuse
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 1141 - 1146
  • [24] A multicenter phase II of S-1 in gemcitabine-refractory biliary tract cancer
    Suzuki, E.
    Ikeda, M.
    Okusaka, T.
    Nakamori, S.
    Ohkawa, S.
    Nagakawa, T.
    Boku, N.
    Yamagimoto, H.
    Sugimori, K.
    Furuse, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [25] A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer
    Han, Boram
    Kim, Bum Jun
    Kim, Hyeong Su
    Choi, Dae Ro
    Shim, Byoung Yong
    Lee, Kyung Hee
    Kim, Jin Won
    Kim, Jung Han
    Song, Hunho
    Kim, Jong Hyeok
    Park, Choong Kee
    Lee, Jung Woo
    Kim, Min-Jeong
    Zang, Dae Young
    JOURNAL OF CANCER, 2021, 12 (03): : 912 - 917
  • [26] S-1 as Monotherapy or in Combination With Leucovorin as Second-Line Treatment in Gemcitabine-Refractory Advanced Pancreatic Cancer: A Randomized, Open-Label, Multicenter, Phase II Study
    Ge, Feijiao
    Xu, Nong
    Bai, Yuxian
    Ba, Yi
    Zhang, Yanqiao
    Li, Fei
    Xu, Huayan
    Jia, Ru
    Wang, Yan
    Lin, Li
    Xu, Jianming
    ONCOLOGIST, 2014, 19 (11): : 1133 - 1134
  • [27] Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer
    Hunho Song
    Boram Han
    Choong Kee Park
    Jong Hyeok Kim
    Jang Yong Jeon
    In-Gyu Kim
    Hyo Jung Kim
    Joo Young Jung
    Jung Han Kim
    Jung Hye Kwon
    Geundoo Jang
    Ho Young Kim
    Hyeong Su Kim
    Dae Ro Choi
    Dae Young Zang
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 845 - 852
  • [28] Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer
    Song, Hunho
    Han, Boram
    Park, Choong Kee
    Kim, Jong Hyeok
    Jeon, Jang Yong
    Kim, In-Gyu
    Kim, Hyo Jung
    Jung, Joo Young
    Kim, Jung Han
    Kwon, Jung Hye
    Jang, Geundoo
    Kim, Ho Young
    Kim, Hyeong Su
    Choi, Dae Ro
    Zang, Dae Young
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (04) : 845 - 852
  • [29] Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer (PC) in Japan and Taiwan: GEST study
    Ioka, T.
    Ikeda, M.
    Ohkawa, S.
    Yanagimoto, H.
    Fukutomi, A.
    Sugimori, K.
    Baba, H.
    Yamao, K.
    Shimamura, T.
    Chen, J.
    Mizumoto, K.
    Furuse, J.
    Funakoshi, A.
    Hatori, T.
    Yamaguchi, T.
    Egawa, S.
    Sato, A.
    Ohashi, Y.
    Cheng, A.
    Okusaka, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [30] A randomized phase II trial of adjuvant chemotherapy with S-1 versus S-1 and gemcitabine (GS) versus gemcitabine alone (GEM) in patients with resected pancreatic cancer (CAP-002 study).
    Yoshitomi, Hideyuki
    Shimizu, Hiroaki
    Yoshidome, Hiroyuki
    Ohtsuka, Masayuki
    Kato, Atsushi
    Furukawa, Katsunori
    Takayashiki, Tsukasa
    Kuboki, Satoshi
    Okamura, Daiki
    Suzuki, Daisuke
    Nakajima, Masayuki
    Aida, Toshiaki
    Miyazaki, Masaru
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345